Clinical Laserthermia Systems Announces Agreement with KASRAEIAN Urology to Treat Prostate Cancer Patients with TRANBERG Thermal Therapy System
Lund, Sweden – November 9, 2023 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that their US subsidiary CLS Americas has signed a Mobile Service Provider (MSP) Agreement with KASRAEIAN Urology of Jacksonville, FL in The U.S.
Under the agreement, CLS provides its FDA 510(k) cleared TRANBERG Thermal Therapy System in a bundled service offering, including sterile disposables, training, and on-site clinical and technical support to KASRAEIAN Urology physicians and staff during procedures. KASRAEIAN Urology utilizes the latest technologies, devices, and treatments in order to provide the best options and outcomes for their prostate cancer patients.
“CLS Americas is very pleased with the increasing market adoption of our Mobile Services Program by leading professional clinics like KASRAEIAN Urology. It allows them to gain access to our image-guided TRANBERG focal laser ablation system without any capital equipment expense,” said Michael Magnani, president of CLS Americas. “We are thrilled to see leading physicians, clinics, and organizations adopting our TRANBERG Laser to provide prostate cancer treatments.”
"CLS Americas mobile services offering to urology clinics with prostate cancer programs is being well received and with adoption showing good progress. I can proudly say that the hard work by CLS Americas, to deliver best in class services, is generating results.", says Dan J Mogren, CEO of CLS AB.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
About Kasraeian Urology
For more information, visit: Jacksonville, FL Urology | Kasraeian Urology
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: clinicallaser.se.